Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
15.96 USD   +13.68%
09/30Chardan Lifts Price Target on Rocket Pharmaceuticals to $65 From $62, Maintains Buy Rating
MT
09/30Evercore ISI Adjusts Rocket Pharmaceuticals Price Target to $75 From $65, Maintains Outperform Rating
MT
09/30Transcript : Rocket Pharmaceuticals, Inc. - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Raymond James Adjusts Rocket Pharmaceuticals' Price Target to $24 From $22, Maintains Outperform Rating

08/09/2022 | 10:58am EDT


© MT Newswires 2022
All news about ROCKET PHARMACEUTICALS, INC.
09/30Chardan Lifts Price Target on Rocket Pharmaceuticals to $65 From $62, Maintains Buy Rat..
MT
09/30Evercore ISI Adjusts Rocket Pharmaceuticals Price Target to $75 From $65, Maintains Out..
MT
09/30Transcript : Rocket Pharmaceuticals, Inc. - Special Call
CI
09/30Rocket Pharmaceuticals Says Danon Disease Therapy Showed Clinical Benefit in Phase 1 St..
MT
09/30 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A..
BU
09/30Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A5..
CI
09/27UBS Adjusts Rocket Pharmaceuticals Price Target to $62 From $68, Maintains Buy Rating
MT
09/27Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
BU
09/20Rocket Pharmaceuticals : VOTING AGREEMENT - Form 8-K
PU
09/20Rocket Pharmaceuticals, Inc. : Entry into a Material Definitive Agreement, Other Events, F..
AQ
More news
Analyst Recommendations on ROCKET PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 0,13 M - -
Net income 2022 -203 M - -
Net cash 2022 230 M - -
P/E ratio 2022 -5,22x
Yield 2022 -
Capitalization 1 054 M 1 054 M -
EV / Sales 2022 6 593x
EV / Sales 2023 11,2x
Nbr of Employees 151
Free-Float 93,8%
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 15,96 $
Average target price 55,91 $
Spread / Average Target 250%
EPS Revisions
Managers and Directors
Gaurav D. Shah Chief Executive Officer & Director
Kinnari Patel President & Chief Operating Officer
John C. Militello Treasurer, Chief Financial & Accounting Officer
Roderick T. Wong Chairman
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ROCKET PHARMACEUTICALS, INC.-26.89%1 054
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044